SRR4195685
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.510
- INTERFERON_ALPHA_RESPONSE+0.450
- MYC_TARGETS_V1+0.410
- INTERFERON_GAMMA_RESPONSE+0.330
- E2F_TARGETS+0.320
- OXIDATIVE_PHOSPHORYLATION+0.270
- MTORC1_SIGNALING+0.260
- UV_RESPONSE_UP+0.240
- DNA_REPAIR+0.230
- UNFOLDED_PROTEIN_RESPONSE+0.230
Top 10 suppressed
- UV_RESPONSE_DN-0.360
- ANDROGEN_RESPONSE-0.310
- PROTEIN_SECRETION-0.280
- TGF_BETA_SIGNALING-0.200
- BILE_ACID_METABOLISM-0.180
- PANCREAS_BETA_CELLS-0.160
- ANGIOGENESIS-0.150
- COMPLEMENT-0.130
- HEME_METABOLISM-0.120
- XENOBIOTIC_METABOLISM-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-22-5471-01A-01R-1635-07 | — | cohortSQ2 | 0.872 |
| 2 | DRR168607 | — | — | 0.811 |
| 3 | sclc1500_S38.txt | — | cohortMD1 | 0.798 |
| 4 | SRR12475141 | — | — | 0.796 |
| 5 | TCGA-A7-A6VW-01A-21R-A33J-07 | — | E | 0.793 |
| 6 | d9780581-dfca-4e83-9bb4-4836f22d910e | — | — | 0.790 |
| 7 | TCGA-QK-A6IG-01A-11R-A31N-07 | — | — | 0.777 |
| 8 | TCGA-A2-A0D0-01A-11R-A00Z-07 | — | E | 0.777 |
| 9 | TCGA-CV-5966-01A-11R-1686-07 | — | — | 0.771 |
| 10 | TCGA-F7-A620-01A-11R-A28V-07 | — | — | 0.765 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.510 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.450 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.410 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.330 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.320 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.270 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.260 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.240 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.230 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.230 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.180 | Temsirolimus | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.160 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.150 | Idelalisib | — uncovered |
| APOPTOSIS | 0.140 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.140 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.140 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.140 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.130 | Idelalisib | — uncovered |
| MYOGENESIS | 0.130 | Inavolisib | — uncovered |